Community Trials Essential to Broad Knowledge

VBCC - September 2010, Volume 1, No 4 - VBCC Perspectives
Edmund J. Pezalla, MD, MPH
Founder and Consultant
EZ Pezalla Independent Consultant
Wethersfield, CT

Several sessions at the recent ASCO meeting considered new standards for community-based oncology research and the development of comparative effectiveness research (CER) methods.

Community-based oncology trials play an important role in developing treatment strategies and options. In recent years, however, clinical trial participation in the United States has been on the decline, which limits the population available to researchers and makes it difficult to achieve the diversity needed to reflect the actual experience of patients across the country. Encouraging high-quality community-based trials will remedy this and remove barriers such as the need to travel to major urban medical centers.

Problems of cost will continue to exist but we should note that for manufacturer-sponsored drug trials, the pharmaceutical firm will cover the cost of the experimental treatment and most insurers will cover the routine care needed for the treatment of cancer. In all cases, however, guidance from the health plan on reimbursement should be sought before enrolling in a trial. This may not make trial participation affordable for all but should go some ways towards helping many more patients join a trial. In addition, with the passage of the Patient Protection and Affordable Care Act in March 2010, insurers will be prohibited from dropping or limiting coverage because an individual chooses to participate in a clinical trial effective January 1, 2014. This applies to all clinical trials that treat cancer or other life-threatening diseases.

As noted in “Trial Participation Hampered by Costs” (see page 11), patients continue to express concerns about the cost of clinical trial participation, and Dr Weckstein’s prescriptions for mitigating these financial barriers appear sound. Covering the largely unseen costs of copays and deductibles through legislation would be a huge boon, as would public funding for patient costs associated with trial participation.

The development of sophisticated CER methodologies should also help to fill the gap for clinical trials since these approaches may augment, or in some cases, replace, the need for an expensive randomized controlled trial (RCT).

It is my hope that a combination of renewed interest in clinical trials at the community level with alternatives to RCTs in the case of already approved drugs will yield better medical evidence and better patient outcomes.

Related Items
The NCCN Evidence Blocks and Clinical Practice Guidelines: Identifying Truth
Robert W. Carlson, MD, Al B. Benson III, MD, FACP
VBCC - March 2016, Vol 7, No 2 published on March 21, 2016 in Online First, VBCC Perspectives
The NCCN New Tool to Assess Value Discourages Patients’ Hope
Robert Goldberg, PhD
VBCC - November 2015, Vol 6, No 10 published on November 12, 2015 in VBCC Perspectives
AstraZeneca Commentary on Oncology Value Tools
Diane Sullivan
VBCC - October 2015, Vol 6, No 9 published on October 17, 2015 in VBCC Perspectives
ASCO’s Value Framework a Powerful Tool for Shared Decision-Making
Neil B. Minkoff, MD
VBCC - August 2015, Vol 6, No 7 published on August 18, 2015 in VBCC Perspectives
The Role of Oncologists in Defining the Value of Cancer Therapy
Michael Kolodziej, MD
VBCC - August 2015, Vol 6, No 7 published on August 18, 2015 in VBCC Perspectives
Emerging Tools for Assessing Value: Pros and Cons
Kirby J. Eng, RPh
VBCC - August 2015, Vol 6, No 7 published on August 18, 2015 in VBCC Perspectives
ASCO’s Value Framework Promoting Accountability and Transparency
Joseph Morse
VBCC - August 2015, Vol 6, No 7 published on August 18, 2015 in VBCC Perspectives
ASCO’s Net Health Benefit: A Palliative Care Regimen Scores Higher than Active Treatment
Pamela Pelizzari, MPH, Bruce Pyenson, FSA, MAAA
VBCC - August 2015, Vol 6, No 7 published on August 18, 2015 in VBCC Perspectives
Addressing the Value of New Cancer Treatment Options Using the ASCO Model
Philip E. Johnson, MS, RPh, FASHP
VBCC - August 2015, Vol 6, No 7 published on August 18, 2015 in VBCC Perspectives
The Missing Elements in Our Value-Based Care Discussions
Kevin Cast
VBCC - August 2015, Vol 6, No 7 published on August 18, 2015 in VBCC Perspectives
Last modified: May 28, 2014
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology